Literature DB >> 23018824

Bisphosphonate safety and efficacy in chronic kidney disease.

Susan M Ott1.   

Abstract

A new population-based study of elderly patients hospitalized for a fracture and treated with an oral bisphosphonate finds no increased risk of acute kidney injury. The safety and efficacy of bisphosphonates may be different in patients with chronic kidney disease (CKD). The effects on vascular calcifications need further study, because low bone turnover might exacerbate vascular calcifications in patients with CKD. Even if bisphosphonates prove safe, their efficacy in this population is uncertain.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 23018824     DOI： 10.1038/ki.2012.253

Source DB:  PubMed          Journal:  Kidney Int        ISSN： 0085-2538            Impact factor:   10.612


  9 in total

1.  New insights into human farnesyl pyrophosphate synthase inhibition by second-generation bisphosphonate drugs.

Authors:  D Fernández; R Ramis; J Ortega-Castro; R Casasnovas; B Vilanova; J Frau
Journal:  J Comput Aided Mol Des       Date:  2017-06-19       Impact factor: 3.686

2.  Bisphosphonates and mortality in women with CKD and the presence or absence of cardiovascular disease.

Authors:  Robert M Perkins; H Lester Kirchner; Kunihiro Matsushita; Ion D Bucaloiu; Evan Norfolk; James E Hartle
Journal:  Clin J Am Soc Nephrol       Date:  2014-02-27       Impact factor: 8.237

Review 3.  Therapy for patients with CKD and low bone mineral density.

Authors:  Susan M Ott
Journal:  Nat Rev Nephrol       Date:  2013-10-08       Impact factor: 28.314

Review 4.  Bisphophonates in CKD patients with low bone mineral density.

Authors:  Wen-Chih Liu; Jen-Fen Yen; Cheng-Lin Lang; Ming-Tso Yan; Kuo-Cheng Lu
Journal:  ScientificWorldJournal       Date:  2013-12-31

5.  Zoledronate dysregulates fatty acid metabolism in renal tubular epithelial cells to induce nephrotoxicity.

Authors:  Lili Cheng; Mengmeng Ge; Zhou Lan; Zhilong Ma; Wenna Chi; Wenhua Kuang; Kun Sun; Xinbin Zhao; Ye Liu; Yaqian Feng; Yuedong Huang; Maoguo Luo; Liping Li; Bin Zhang; Xiaoyu Hu; Lina Xu; Xiaohui Liu; Yi Huo; Haiteng Deng; Jinliang Yang; Qiaoran Xi; Yonghui Zhang; Julie A Siegenthaler; Ligong Chen
Journal:  Arch Toxicol       Date:  2017-09-04       Impact factor: 5.153

Review 6.  Molecular Abnormalities Underlying Bone Fragility in Chronic Kidney Disease.

Authors:  Yoshiko Iwasaki; Junichiro James Kazama; Masafumi Fukagawa
Journal:  Biomed Res Int       Date:  2017-03-22       Impact factor: 3.411

Review 7.  Chronic kidney disease and fragility fracture.

Authors:  Junichiro James Kazama
Journal:  Clin Exp Nephrol       Date:  2016-12-23       Impact factor: 2.801

8.  Suppression of bone remodeling associated with long-term bisphosphonate treatment is mediated by microRNA-30a-5p.

Authors:  Xia Li; Ruisheng Xu; Jun-Xing Ye; Feng-Lai Yuan
Journal:  Bioengineered       Date:  2022-04       Impact factor: 6.832

9.  Alendronate use and bone mineral density gains in women with moderate-severe (stages 3B-5) chronic kidney disease: an open cohort multivariable and propensity score analysis from Funen, Denmark.

Authors:  M Sanni Ali; Martin Ernst; Danielle E Robinson; Fergus Caskey; Nigel K Arden; Yoav Ben-Shlomo; Mads Nybo; Katrine H Rubin; Andrew Judge; Cyrus Cooper; M K Javaid; Anne P Hermann; Daniel Prieto-Alhambra
Journal:  Arch Osteoporos       Date:  2020-06-01       Impact factor: 2.617
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.